Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FEDERAL JUDGE LORD's ADDRESS AT FEB. 29 DALKON SHIELD SETTLEMENT HEARING

Executive Summary

On Feb. 29, Eighth Circuit federal judge Miles Lord delivered an unusual address to three A. H. Robins executives at a settlement hearing for seven liability cases associated with the use of the Dalkon Shield. Judge Lord's comments -- a combination of lecture and sermon -- received coverage in the natl. media under such headlines as The Washington Post's March 2 story, "U.S. Judge Assails Officers of Dalkon Shield Maker." On the following four pages, "The Pink Sheet" is reproducing for the record the full text of the judge's speech with his comments on corporate responsibility, liability trial tactics, and liability law reform. "The Pink Sheet" is also reproducing in full a statement by A. H. Robins in response to the Lord speech. Lord addressed his comments specifically to Robins President E. Claiborne Robins, Jr., Corporate VP and General counsel William Forrest, Jr., and Senior VP Research and Development Carl Lunsford. The paragraphing in this reproduced version is the same as the prepared copy of Judge Lord's remarks. Indents have been added by the editors of "The Pink Sheet" to make the copy easier to read.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel